Panama - englanti - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

f. hoffmann-la roche ltd - pertuzumab - pertuzumab....1200 mg / trastuzumab....600 mg

Euroopan unioni - englanti - myHealthbox

genzyme therapeutics ltd - alemtuzumab - concentrate for solution for infusion - 12 mg alemtuzumab in 1.2 ml (10 mg/ml) - multiple sclerosis - selective immunosuppressants - indicated for adult patients with relapsing remitting multiple sclerosis (rrms) with active disease defined by clinical or imaging features

Israel - englanti - Ministry of Health

pfizer pharmaceuticals israel ltd - gemtuzumab ozogamicin - powder for concentrate for solution for infusion - gemtuzumab ozogamicin 5 mg/vial - gemtuzumab - mylotarg is indicated for the treatment of newly-diagnosed cd33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older.mylotarg is indicated for the treatment of relapsed or refractory cd33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older…….

Kenia - englanti - Pharmacy and Poisons Board

f. hoffman-la roche ltd grenzacherstrasse 124, ch-4070, basel, switzerland - pertuzumab and trastuzumab - solution for injection - each ml of solution contains 80 mg of pertuzumab… - pertuzumab and trastuzumab

Euroopan unioni - englanti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - multiple myeloma - antineoplastic agents - empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).

Euroopan unioni - englanti - EMA (European Medicines Agency)

pfizer europe ma eeig - inotuzumab ozogamicin - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents - besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory cd22-positive b cell precursor acute lymphoblastic leukaemia (all). adult patients with philadelphia chromosome positive (ph+) relapsed or refractory b cell precursor all should have failed treatment with at least 1 tyrosine kinase inhibitor (tki).

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - alemtuzumab 10 mg/ml - concentrate for infusion - 10 mg/ml - active: alemtuzumab 10 mg/ml excipient: dibasic sodium phosphate disodium edetate dihydrate monobasic potassium phosphate polysorbate 80 potassium chloride sodium chloride - treatment of relapsing forms of multiple sclerosis (ms) for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses.

Euroopan unioni - englanti - EMA (European Medicines Agency)

pfizer europe ma eeig - gemtuzumab ozogamicin - leukemia, myeloid, acute - antineoplastic agents - mylotarg is indicated for combination therapy with daunorubicin (dnr) and cytarabine (arac) for the treatment of patients age 15 years and above with previously untreated, de novo cd33-positive acute myeloid leukaemia (aml), except acute promyelocytic leukaemia (apl).

Euroopan unioni - englanti - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - breast neoplasms - antineoplastic agents - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - pertuzumab 420mg equivalent to 30 mg/ml - concentrate for infusion - 420 mg/14ml - active: pertuzumab 420mg equivalent to 30 mg/ml excipient: glacial acetic acid histidine polysorbate 20 sucrose water for injection - metastatic breast cancer perjeta is indicated in combination with trastuzumab and docetaxel for patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for their metastatic disease.